Michael Morrissey News
-
Exelixis Inc. won U.S. regulatory approval for cabozantinib to treat thyroid cancer patients, giving the company its first marketed product.
-
Biogen Idec Inc., the world’s largest maker of multiple sclerosis treatments, named George Scangos , 62, chief executive officer, effective July 15.
-
Exelixis Inc., a biotechnology company with no approved products, plunged the most in 11 years after failing to agree with U.S. regulators on special rules for a study of its experimental prostate cancer drug.
-
Exelixis Inc. ’s experimental pill reduced malignant growths in the bones of 86 percent of men with prostate cancer and cut the spread of tumor cells in one-fourth of women with ovarian cancer in a company study.
-
Biogen Idec Inc., the world’s largest maker of multiple sclerosis treatments, will name George A. Scangos chief executive officer as early as today, according to a person familiar with the hiring process.
-
Exelixis Inc. and Bristol-Myers Squibb Co. ’s experimental drug delayed the spread of an aggressive brain cancer, a study found.
-
Exelixis Inc. is working with Goldman Sachs Group Inc. to prepare for potential takeover offers after its experimental drug helped prostate-cancer patients in a study, said people with knowledge of the matter.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page